Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid;Tratamiento de las epistaxis en la telangiectasia hemorrágica hereditaria (enfermedad de Rendu-Osler-Weber) con ácido tranexámico

Acta Otorrinolaringologica Espanola

Volumn 58, Issue 4, 2007, Pages 129-132

  Morales Angulo, Carmelo ^a,c   Del Molino, Alfonso Pérez ^a   Zarrabeitia, Roberto ^a   Fernández, África ^b   Sanz Rodríguez, Francisco ^b   Botella, Luisa María ^b  

^a HOSPITAL SIERRALLANA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c NONE   (Spain)

Author keywords

Epistaxis; Hereditary haemorrhagic telangiectasia; Tranexamic acid; Treatment

Indexed keywords

TRANEXAMIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; EPISTAXIS; FEMALE; HUMAN; MALE; MORBIDITY; PATIENT SATISFACTION; PROSPECTIVE STUDY; RENDU OSLER WEBER DISEASE;

EID: 34547883938     PISSN: 00016519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-6519(07)74897-5     Document Type: Article

References (29)

1. Morales Angulo C, Megía López R, Del Valle Zapico A, Mazón Gutiérrez A, García Mantilla J, Rama Quintela J. La enfermedad de Rendu-Osler-Weber (telangiectasia hemorrágica hereditaria). Presentación de 30 casos. Acta Otorrinolaringol Esp. 1997;48:625-9.
2. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-B binding protein of endothelial cells, is the gene fo hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345-51.
3. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marodel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13:189-95.
4. Cole SG, Begbie HE, Wallace M, Showlin CL. A new locus for hereditary haemorhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet. 2005;42:577-82.
5. Plauchu H, Chadavérien JP, Bideau A, Robert JM. Age related profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32:291-7.
6. Pérez del Molino A, Zarrabeitia R, Fernández A. Telangiectasia hemorrágica hereditaria. Med Clin (Barc). 2005;124:583-7.
7. Morales-Angulo C, Del Valle A. Hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg. 1998;119:223.
8. Aassar OS, Craig M, Friedman CM, White RI. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 1991;101:977-80.
9. Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918-24.
10. Morais D, Ramírez B, Santos J. El tratamiento local esclerosante con etoxiesclerol en la patología ORL: enfermedad de Rendu-Osler, granulomas, angiomas. Acta Otorrinolaringol Esp. 2002;53:658-61.
11. Ramírez B, Morais D, Condado MA, Marcos M, Martín G, Poncela M. Una nueva sustancia esclerosante en el tratamiento de la enfermedad de Rendu-Osler-Weber. Acta Otorrinolaringol Esp. 2000;51:36-9.
12. Escalante A, Pinzón E, Belloso A, Pozo A. Cobaltoterapia en el tratamiento de la enfermedad de Rendu-Osler. Apropósito de dos casos. Acta Otorrinolaringol Esp. 1988;39:57-9.
13. Urpegui A, Sancho EM, Royo JY, Valles H. Embolización selectiva terapéutica en epistaxis incoercibles. Acta Otorrinolaringol Esp. 2001;52:508-12.
14. Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med. 1994;330:1789-90.
15. Annichino-Bizzacchi JM, Facchini RM, Torresan MZ, Arruda VR. Hereditary hemorrhagic telangiectasia response to aminocaproic acid treatment. Thromb Res. 1999;96:73-6.
16. Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med. 2001;345:926.
17. Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med. 2001;161:767.
18. Pérez del Molino A, Zarrabeitia R, Fernández A, Botella LM. Eficacia del ácido tranexámico en un pacientes con THH y epistaxis masiva. Med Clin (Barc). 2004;123:118-9.
19. Korzenik JR, Topazian MD, White R. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med. 1994:331:1236.
20. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 1989;32:291-7.
21. Sadick H, Raimin N, Oulmi J, Karl H, Bergler W. Plasma surgery and topical estriol: effects on the nasal mucosa and long-term reults in patients with Osler's disease. Otolaryngol Head Neck Surg. 2003;128:233-8.
22. Byahatti SV, Rebeiz EE, Shapshay SM. Hereditary hemorrhagic telangiectasia: what the otolaryngologist should know. Am J Rhinol. 1997;11:55-62.
23. Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol. 1971;107:571-3.
24. Watanabe M, Hanawa S, Morishima T. [Fibrinolytic activity in cutaneous lesions of hereditary hemorrhagic telangiectasia]. Nippon Hifuka Gakkai Zasshi. 1985;95:11-6.
25. Manucci PM. Drug therapy: hemostatic drugs. N Engl J Med. 1998;339:245-53.
26. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation: influence of omega-aminocarboxylic acids. Biochim Biophys Acta. 1975;393:55-65.
27. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta. 1981;673:75-85.
28. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29:236-61.
29. Andersson L, Nilson IM, Colleen S, Granstrand B, Melander B. Role of urokinasa and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann N YAcad Sci. 1968;146:642-58.